Clinical Trials Logo

Pancreatic Cancer Non-resectable clinical trials

View clinical trials related to Pancreatic Cancer Non-resectable.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06375967 Not yet recruiting - Clinical trials for Biliary Tract Neoplasms

EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)

CARPEGIEM
Start date: June 2024
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients.

NCT ID: NCT06361030 Not yet recruiting - Pancreatic Cancer Clinical Trials

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer

NCT ID: NCT05802485 Not yet recruiting - Clinical trials for Pancreatic Cancer Non-resectable

PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT

Start date: April 30, 2023
Phase: N/A
Study type: Interventional

The study consists of a 25 ml blood sample collection: - Before the start of treatment - Approximately 2 months after the start of induction chemotherapy - At the end of induction chemotherapy - Prior to local treatment (radiotherapy, surgery) - At the time of tumor progression Collection of tumor material: - During the initial diagnostic biopsy - On the operating room in case of surgery - At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.

NCT ID: NCT05047991 Not yet recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Start date: October 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, open-lable, parallel-controlled phase II study of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma. The purpose of this study is to evaluate the differences of safety and efficacy of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma.